文献速递垂体与肾上腺疾病肥胖与代谢综合征

先天性肾上腺皮质增生症纵向研究中的心血管疾病危险因素与代谢疾病

Cardiovascular Disease Risk Factors and Metabolic Morbidity in a Longitudinal Study of Congenital Adrenal Hyperplasia.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该纵向研究纳入57例在儿童期和成年期均随访至少5年的经典先天性肾上腺皮质增生症(CAH)患者,并与美国一般人群比较。结果显示CAH患者儿童期肥胖、高血压、胰岛素抵抗、空腹高血糖和低HDL患病率显著更高,成年期肥胖、高血压和胰岛素抵抗风险仍升高。代谢异常与治疗相关因素及家族因素有关。

要点

  • CAH患者儿童期即出现肥胖、高血压、胰岛素抵抗等代谢异常。
  • 儿童期较高盐皮质激素剂量与高血压和低HDL相关。
  • 成年期雄烯二酮抑制与高血压和高LDL相关,睾酮抑制与胰岛素抵抗相关。

核心结论

  • CAH患者在年轻时就出现代谢疾病,与治疗相关和家族因素有关。
  • 应合理使用糖皮质激素和盐皮质激素。

研究设计与样本

  • 纵向研究,纳入57例在儿童期和成年期均随访至少5年的经典CAH患者,并与NHANES数据比较。

主要发现

  • 与US人群相比,CAH患者儿童期肥胖、高血压、胰岛素抵抗、空腹高血糖和低HDL患病率更高(P < 0.001)。
  • 成年期肥胖(P = 0.024)、高血压(P < 0.001)和胰岛素抵抗(P < 0.001)患病率更高。
  • 队列中肥胖、高血压、空腹高血糖和高甘油三酯血症在10岁前开始。
  • 儿童期盐皮质激素剂量增加与高血压(P = 0.0015)和低HDL(P = 0.0021)相关。
  • 成年期雄烯二酮抑制与高血压(P = 0.002)和高LDL(P = 0.0039)相关,睾酮抑制(P = 0.003)与胰岛素抵抗相关。

关键数值与推荐

  • 儿童期母亲肥胖与成年期肥胖风险增加相关(P = 0.0021)。
  • 儿童期17-羟孕酮升高(可能反映疾病控制不佳)与高胆固醇风险降低相关(P = 0.0049)。

临床怎么用

  • 对CAH患者应监测代谢指标,从儿童期开始关注肥胖、高血压、胰岛素抵抗等。
  • 糖皮质激素和盐皮质激素的使用应谨慎,避免过度治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Patients with congenital adrenal hyperplasia (CAH) are exposed to hyperandrogenism and supraphysiologic glucocorticoids, both of which can increase risk of metabolic morbidity. OBJECTIVE: Our aim was to evaluate cardiovascular and metabolic morbidity risk in a longitudinal study of patients with CAH spanning both childhood and adulthood. DESIGN AND SETTING: Patients with classic CAH followed for a minimum of 5 years during both childhood and adulthood (n = 57) at the National Institutes of Health were included and compared with the US general population using NHANES data. MAIN OUTCOME MEASURES: Obesity, hypertension, insulin resistance, fasting hyperglycemia, and dyslipidemia. RESULTS: Compared to the US population, patients with CAH had higher (P < 0.001) prevalence of obesity, hypertension, insulin resistance, fasting hyperglycemia, and low high-density lipoprotein (HDL) during childhood and obesity (P = 0.024), hypertension (P<0.001), and insulin resistance (P < 0.001) during adulthood. In our cohort, obesity, hypertension, fasting hyperglycemia, and hypertriglyceridemia began prior to age 10. During childhood, increased mineralocorticoid dose was associated with hypertension (P = 0.0015) and low HDL (P = 0.0021). During adulthood, suppressed androstenedione was associated with hypertension (P = 0.002), and high low-density lipoprotein (P = 0.0039) whereas suppressed testosterone (P = 0.003) was associated with insulin resistance. Elevated 17-hydroxyprogesterone, possibly reflecting poor disease control, was protective against high cholesterol (P = 0.0049) in children. Children whose mothers were obese (maternal obesity) had increased risk of obesity during adulthood (P = 0.0021). Obesity, in turn, contributed to the development of hypertension, insulin resistance, and hypertriglyceridemia in adulthood. CONCLUSION: Patients with CAH develop metabolic morbidity at a young age associated with treatment-related and familial factors. Judicious use of glucocorticoid and mineralocorticoid is warranted.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Torky A, Sinaii N, Jha S, et al. Cardiovascular Disease Risk Factors and Metabolic Morbidity in a Longitudinal Study of Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2021. PMID: 33677504. doi:10.1210/clinem/dgab133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。